media centre
oNKo-innate named Australian Emerging Company of the Year 2021
27 October

Click through to view the press release
media centre
All media
All media
Twitter
Feed
Feed
Feed
news
news
publications
publications
22 September
Iva Nikolic promoted to Chief Technology Officer
27 October
oNKo-innate named Australian Emerging Company of the Year 2021
10 July
The cancer–natural killer cell immunity cycle
10 June
Monash University and oNKo-innate Announce Research Partnership
23 April
Onko-Innate, Gilead, Kite Work On NK Cancer Immunotherapies
22 April
Immunotherapy biotech scores Gilead partnership
22 April
Interest builds in next-generation cancer immunotherapies
22 April
Gilead, oNKo-innate to develop NK cells-focused cancer immunotherapies
22 April
Gilead, Kite pen natural killer pact with little-known Australian cell therapy player
22 April
Amid remdesivir craze Gilead finds time for another oncology pact — looping in all things NK cells
21 April
Announcing research collaboration with Gilead and Kite
17 March
You Have Got a Fast CAR: Chimeric Antigen Receptor NK Cells in Cancer Therapy
21 August
Impact of Tumor and Immunological Heterogeneity on the Anti-Cancer Immune Response
30 July
A Gene Signature Predicting Natural Killer Cell Infiltration and Improved Survival in Melanoma Patients
12 May
Quantifying NK cell growth and survival changes in response to cytokines and regulatory checkpoint blockade helps identify optimal culture and expansion conditions
6 March
Congratulations to our CSO for winning the 2019 Jacques Miller Medal
23 January
The Emergence of Natural Killer Cells as a Major Target in Cancer Immunotherapy
24 May
Molecular insight into targeting the NK cell immune response to cancer
24 September
The life and death of immune cell types: the role of BCL-2 anti-apoptotic molecules
18 September
Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells
24 February
IL-15 signaling in NK cell cancer immunotherapy
7 February
Targeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis
19 August
Targeting natural killer cells in cancer immunotherapy
17 July
CIS is a potent checkpoint in NK cell-mediated tumor immunity
29 January
A crucial role for the homeodomain transcription factor Hhex in lymphopoiesis
12 April
IL-15 transpresentation promotes both human T-cell reconstitution and T-cell-dependent antibody responses in vivo
16 January
IL-15 trans-presentation promotes human NK cell development and differentiation in vivo
Twitter
1 January